National University Heart Centre Singapore, Singapore.
School of Medicine, University of Auckland, New Zealand.
Am J Cardiol. 2019 Sep 15;124(6):899-906. doi: 10.1016/j.amjcard.2019.06.004. Epub 2019 Jun 24.
The association of diabetes mellitus (DM) with cardiac resynchronization therapy (CRT) response and cardiovascular outcomes in Asian patients with heart failure (HF) is unclear. This study aims to investigate the effects of DM on CRT response and cardiovascular outcomes in Asian HF patients. Consecutive Asian HF patients receiving CRT were enrolled in the Prospective Evaluation of Asian with CRT for Heart Failure (PEACH) study from 2011 to 2017. CRT response and super-response were defined as decrease in end-systolic volume index ≥15% and ≥30%, respectively. Primary endpoint was time to composite of HF-hospitalization and all-cause mortality. Among 161 patients followed for 3.3 ± 1.5 years (age 66.7 ± 11.2 years, 22% females, mean QRS duration 154.3 ± 22.4 ms, 83% left bundle branch block), 84 (52%) were CRT responders and 57 (35%) were super-responders. Of 82 (51%) patients with DM (100% type 2, mean HbA1c 7.3 ± 1.9%), 35 (43%) were responders. DM attenuated reverse remodeling (CRT response: AOR 0.44, 95% confidence interval [CI] 0.20 to 0.98, p < 0.05; super-response: AOR 0.42, 95% CI 0.18 to 0.97, p <0.05), and DM increased HF-hospitalization and all-cause mortality (AHR 1.68, 95% CI 1.00 to 2.82, p = 0.05). The extent of CRT-response correlates with higher event-free survival (CRT response: AHR 0.5, 95% CI 0.30 to 0.81, p = 0.005; super-response: AHR 0.27, 95% CI 0.14 to 0.52, p < 0.001). In conclusion, the extent of reverse remodeling post-CRT is the strongest predictor of event free survival. However, DM is detrimental to the CRT recipient by attenuating reverse remodeling, inducing end organ dysfunction and is independently associated with worsened clinical outcomes among Asian HF patients.
糖尿病(DM)与心脏再同步治疗(CRT)反应和亚洲心力衰竭(HF)患者心血管结局的关系尚不清楚。本研究旨在探讨 DM 对亚洲 HF 患者 CRT 反应和心血管结局的影响。
2011 年至 2017 年,连续纳入接受 CRT 的亚洲 HF 患者参加前瞻性评估亚洲 CRT 治疗心力衰竭(PEACH)研究。CRT 反应和超级反应定义为左室收缩末期容积指数降低≥15%和≥30%。主要终点是 HF 住院和全因死亡率的复合终点。
在随访 3.3±1.5 年的 161 例患者中(年龄 66.7±11.2 岁,22%为女性,平均 QRS 时限 154.3±22.4ms,83%为左束支传导阻滞),84 例(52%)为 CRT 反应者,57 例(35%)为超级反应者。在 82 例(51%)DM 患者中(100%为 2 型,平均 HbA1c 7.3±1.9%),35 例(43%)为反应者。DM 减弱了逆重构(CRT 反应:OR 0.44,95%CI 0.20 至 0.98,p<0.05;超级反应:OR 0.42,95%CI 0.18 至 0.97,p<0.05),并增加了 HF 住院和全因死亡率(AHR 1.68,95%CI 1.00 至 2.82,p=0.05)。CRT 反应程度与更高的无事件生存率相关(CRT 反应:AHR 0.5,95%CI 0.30 至 0.81,p=0.005;超级反应:AHR 0.27,95%CI 0.14 至 0.52,p<0.001)。
总之,CRT 后逆重构的程度是无事件生存的最强预测因子。然而,DM 通过减弱逆重构、诱导终末器官功能障碍对 CRT 受者有害,并与亚洲 HF 患者的临床结局恶化独立相关。